Advancing New Treatments for Tuberculosis
Core B: BSL3 Advanced Technologies and Animal Infection Core
This project provides specialized facilities and support for scientists working to find new vaccines and treatments for tuberculosis, especially drug-resistant forms.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11135556 on NIH RePORTER |
What this research studies
Tuberculosis (TB) continues to be a serious health problem worldwide, made worse by strains that no longer respond to common antibiotics. Our team is dedicated to understanding how the body fights infections to create better ways to prevent and treat diseases in people. This particular core provides the essential, highly secure laboratories and expert support needed to safely work with the TB bacteria. It also helps coordinate important animal studies that are crucial for developing new vaccines and medicines.
Who could benefit from this research
Good fit: While this specific core does not involve direct patient participation, the research it supports aims to benefit anyone at risk of or suffering from tuberculosis, especially those with drug-resistant forms.
Not a fit: Patients who do not have or are not at risk for tuberculosis would not directly benefit from this research.
Why it matters
Potential benefit: If successful, this work could lead to new vaccines and effective treatments for tuberculosis, offering hope to millions affected by this disease.
How similar studies have performed: This core supports a long-standing program that builds upon previous insights into immune responses, now focusing on the challenging area of TB vaccine development.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Stanley, Sarah a — University of California Berkeley
- Study coordinator: Stanley, Sarah a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.